Navigation Links
Lilly Announces Termination of AIR Insulin Program
Date:3/7/2008

resident, science and technology for Lilly, added "While we are confident in our decision, we also recognize the disappointment of those patients who saw the potential benefit of AIR Insulin. As a leader in diabetes care, we remain committed to our mission to develop innovative, beneficial and cost-effective treatments for diabetic patients. It is also important to emphasize that our decision is not due to any safety concerns observed by Lilly or raised by the independent data safety monitoring board during our development of AIR Insulin."

Lilly is in the process of contacting the clinical investigators conducting the current AIR Insulin clinical trials. Subject to protocols, the trials will be halted and the patients currently enrolled will be moved to other insulin therapy under the supervision of their physicians. In the U.S., Lilly will implement a patient assistance program to provide current clinical trial patients with appropriate financial support to fund their medications and diagnostic supplies through the end of 2008. Based upon further analysis, the company may also pursue a similar program in other regions.

As a result of the decision to terminate the development of AIR Insulin, Lilly will recognize a first-quarter 2008 charge to earnings related to the impairment of Lilly assets, as well as wind-down costs associated with the termination of clinical trials and certain development activities, and costs associated with the patient assistance program. The exact amount of the charge has not yet been determined, but is estimated to be in the range of $90 million to $120 million, or $0.05 to $0.07 per share. Lilly's pro forma adjusted earnings per share guidance remains unchanged at $3.85 to $4.00. On a reported basis, including the charge related to the termination of the AIR Insulin program, as well as the previously announced charge related to the BioMS in-licensing, Lilly now expects 2008 earnings per share to be in the range of $3.73 to $3
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
(Date:12/25/2014)... 2014 The report “Service Quality Management ... & Provider Type - Global Advancements, Worldwide Forecasts & ... in-depth analysis and forecasting of revenues. , Browse ... pages and in-depth TOC on “Service Quality Management (SQM) ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... The first data to show that Neupro® ... are often impaired by pain related to Restless Legs Syndrome ... of Parkinson,s Disease and Movement Disorders in Buenos Aires, ... that the efficacy of rotigotine remained stable over five years ...
... of the desert floor at a place called Ash Meadows, an ... nowhere else in the world. A new Brigham Young University ... a 15,000-year journey, flowing slowly underground from what is now the ... for four decades, and a crack in the Earth,s crust known ...
... CORD:USE Cord Blood Bank, a public cord blood banking facility, ... month their plans to open a family cord blood bank to ... privately bank their baby,s cord blood.  The Team of experts in ... , Joanne Kurtzberg , John Wagner , Eliane ...
Cached Biology Technology:Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 2Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 3Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 4Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 5Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 6Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 7Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 8Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 9Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 10Leading Cord Blood Experts Clarify Their Support of CORD:USE Family Cord Blood Bank 2
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) ... Global Watermarking and Fingerprinting Markets" report to ... This insight provides an overview ... markets. Watermarking aims to control and monitor piracy ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... Cichlid male nannies help out, especially if they,ve been ... Neolamprologus pulcher displays cooperative breeding behavior, where non-parents ... pair. Until now, it was assumed that male subordinates ... published Oct. 12, in the online journal PLoS ...
... available in French . Montreal, October ... funding to advance research in fields ranging from linguistics to ... Chairs were awarded to the following professors who are considered ... at Concordia in the presence of Senator Larry Smith and ...
... A team of investigators from the University of Utah has ... Health (NIH) to fund novel research that may help to ... form of multiple sclerosis. These studies will use an advanced ... who died of primary progressive multiple sclerosis. Multiple sclerosis ...
Cached Biology News:Recognition for 7 Concordia professors 2NIH grant will allow researchers to look for viral cause of most severe form of multiple sclerosis 2
Anti-Goat HRP-DAB Cell & Tissue Staining Kit...
... Chemicon's 3243 provides all the materials necessary for ... in CMV antigen studies analysis. Kit Components: ... (Catalog No. 5122) One bottle containing 220 mL ... Fixation Solution (5X) - (Catalog No. 5113) One ...
ANTI NO-TRYPTOPHAN CONJUGATE...
GOAT ANTI SLI...
Biology Products: